WHITE PLAINS, N.Y., Dec. 5 /PRNewswire-USNewswire/ -- Researchers funded by The Leukemia & Lymphoma Society will present exciting new directions in blood cancer research at the annual American Society of Hematology (ASH) conference this week at the Georgia World Congress Center in Atlanta. Especially noteworthy are new findings in immunotherapies, personalized medicine and targeting transcription factors.
Immunotherapies: Researchers will discuss the current status of anti-
cancer vaccines for patients with B-cell lymphoma; results of early
clinical trials on adoptive T-cell immunotherapies for B-cell malignancies;
new understanding of how immune cells known as natural killer (NK) cells
can eliminate cancer cells; and the emerging role of NK cells in stem cell
-- Vaccines for Lymphomas: Idiotype Vaccines and Beyond, Larry Kwak, M.D.,
Ph.D., The University of Texas M.D. Anderson Cancer Center, Houston,
(Saturday, Dec. 8, 9:30 a.m.).
-- Engineering Antitumor Immunity by T-cell Adoptive Immunotherapy,
Stanley Riddell, M.D., Fred Hutchinson Cancer Research Center,
Seattle, WA, (Dec. 8, 9:30 a.m.).
-- Human Natural Killer Cell Biology, Michael Caligiuri, M.D., The Ohio
State University Comprehensive Cancer Center, Columbus, (Sunday,
Dec. 9, 7:30 a.m.).
-- The Role of Natural Killer Cells in Haploidentical Hematopoietic
Transplantation, Andrea Velardi, M.D., University of Perugia, Italy,
(Dec. 9, 7:30 a.m.).
Targeting transcription factors: Transcription factors are proteins
that control gene expression. Abnormalities in transcription factor
activity are among the most common causes of myeloid and lymphocytic
leukemias and are good targets for new drug development.
-- Targeting RUNX1 in Leukemia, John H. Bushweller, Ph.D., University of
Virginia, Charlottesville; Targeting MLL Fusion Genes in Leukemia,
|SOURCE The Leukemia & Lymphoma Society|
Copyright©2007 PR Newswire.
All rights reserved